Coronavirus disease 2019 in patients with Behcet’s disease: a report of 59 cases in Iran

Shahram, Farhad; Esalatmanesh, Kamal; Khabbazi, Alireza; Rezaieyazdi, Zahra; Mirfeizi, Zahra; Sadeghi, Alireza; Soroosh, Mohsen; Kavosi, Hoda; Alikhani, Majid; Mostafaei, Shayan

doi:10.1007/s10067-021-06004-y

Cited by 11 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may cause a higher frequency of thrombotic COVID‐19 complications in these patients. Interestingly, the frequency of thrombosis did not differ significantly in COVID‐19 patients with APLS or Behçet's disease compared to the general population in previous studies 23–25 …”

Section: The Factors Possible Effects On Covid‐19 Outcomementioning

confidence: 76%

The outcome of COVID‐19 in patients with autoimmune rheumatic diseases: Comparable to the general population or worse?

Batu,

Erden

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Section: The Factors Possible Effects On Covid‐19 Outcomementioning

confidence: 76%

The outcome of COVID‐19 in patients with autoimmune rheumatic diseases: Comparable to the general population or worse?

Batu,

Erden

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

“…A study conducted in Iran on COVID-19 patients having Behcet's disease reported that 63% of cases showed pathergy phenomenon [8]. These lesions differ from the other ulcers seen in the disease on skin and mucosa.…”

Section: Discussionmentioning

confidence: 94%

A Case Report of Behcet's Disease With Thromboses in the Superior Vena Cava and External Iliac Vein

Sayeed¹,

Nashit²,

Bhatty³

et al. 2022

Cureus

View full text Add to dashboard Cite

Behcet's disease (BD), also known as Behcet's syndrome, is a rare, chronic, autoimmune disorder of unknown origin. Its manifestations are thought to be caused by vasculitis, resulting in damage to blood vessels of all sizes throughout the body. We report a 25-year-old Pakistani male who is sexually active and presents with a one-year history of shortness of breath, cough, exertional dyspnea, and neck and facial swelling. On examination, he had severe anemia, mouth ulcers, distended neck and chest veins, prominent abdominal veins, and a scrotal ulcer. After going through mandatory investigations to evaluate the presenting signs and symptoms, thromboses were found in the major veins, including the superior vena cava (SVC) and external iliac vein, as well as a positive pathergy test. Accordingly, a diagnosis of Behcet's disease with cardiomyopathy and venous thrombosis was made. He was treated with anticoagulants, steroids, and azathioprine for six months and subsequently went into remission.

show abstract

“…Literature data have shown that antiviral drugs have been also used in immunocompromised patients, usually at the doses and durations as recommended for the general population. Although the evidence is not strong and data collected are heterogeneous even regarding the different periods of the pandemic (i.e., alpha to delta variants and no vaccines; delta variant, vaccination ongoing; rise of omicron variant, primary vaccination cycle likely complete; emergence of new omicron subvariants, booster vaccination ongoing; summarised in Table I), globally, the data on safety and efficacy are encouraging (29,(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46) (summarised in Tables III and IV). For this reason, the rationale for this PtC is to emphasise that having an ARD does not contraindicate the use of antiviral drugs and that they may be considered in case of mild to moderate COVID-19.…”

Section: Treatment With Antiviral Drugs May Be Considered In Immunoco...mentioning

confidence: 99%

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Talarico

Ramirez

Barreira

et al. 2023

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Patient and public involvement: ePAG were involved in the work as members of the Task Force. Disclaimer: ERN ReCONNET is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission. The content of this publication represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

show abstract

Coronavirus disease 2019 in patients with Behcet’s disease: a report of 59 cases in Iran

Cited by 11 publications

References 32 publications

The outcome of COVID‐19 in patients with autoimmune rheumatic diseases: Comparable to the general population or worse?

The outcome of COVID‐19 in patients with autoimmune rheumatic diseases: Comparable to the general population or worse?

A Case Report of Behcet's Disease With Thromboses in the Superior Vena Cava and External Iliac Vein

ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

Contact Info

Product

Resources

About